a. This is a case of incomplete dominance. | ||
b. This is a case of dominant inheritance. | ||
c. This is a case of recessive inheritance. | ||
d. This is a case of Mendelian inheritance. |
a. The husband is right; he cannot be the father. The father of the child must have AB or B blood type. | ||
b. The husband is right; he cannot be the father. The father of the child must have O blood type. | ||
c. The husband is wrong. He can be the father, if his genotype is AO. | ||
d. The husband is wrong. He can be the father, if his genotype is AA. |
a. 1 in 16 | ||
b. 2 in 16 | ||
c. 3 in 16 | ||
d. 9 in 16 |
a. Yes, because Jane has Bb genotype and Joe has BB genotype, where B stands for the dominant brown eye and b stands for the recessive blue eye. There is a 50% chance that their children would be blue-eyed and have Bb or BB genotype. | ||
b. Yes, because Jane has Bb genotype and Joe has BB genotype, where B stands for the dominant brown eye and b stands for the recessive blue eye. All of their children should be blue-eyed and have Bb or BB genotype. | ||
c. No, because Jane has BB genotype and Joe has Bb genotype, where B stands for the dominant brown eye and b stands for the recessive blue eye. There is a 50% chance that their children would be brown-eyed and have Bb or BB genotype. | ||
d. No, because Jane has Bb genotype and Joe has BB genotype, where B stands for the dominant brown eye and b stands for the recessive blue eye. All of their children should be brown-eyed and have Bb or BB genotype. |
a. Conventional PCR | ||
b. RT-PCR | ||
c. Real-time RT-PCR | ||
d. Subtractive hybridization |
a. 4 | ||
b. 8 | ||
c. 16 | ||
d. 32 |
a. Ribozymes | ||
b. RNAi | ||
c. MicroRNA | ||
d. Riboswithes |
a. In the cgfp gene, the codon usage is C. reinhardtii-conform. | ||
b. The cgfp gene is expressing a different GFP protein sequence. | ||
c. The cgfp gene is expressing a GFP protein with different color. | ||
d. In the cgfp gene, there are fewer introns. |
a. Conventional PCR | ||
b. RT-PCR | ||
c. Real-time RT-PCR | ||
d. Subtractive hybridization. |
a. Radioactive | ||
b. Fluorescent | ||
c. Silver-enhanced gold | ||
d. Photoenhanced |
a. Junk DNA | ||
b. Pseudogene | ||
c. Long repeat | ||
d. Non-coding region |
a. Overlapping chromosome fragments are sequenced continuously without leaving any gap behind. | ||
b. Both ends of random chromosome fragments are sequenced and then the fragments are assembled using computer programs. | ||
c. Scaffolds are sequenced and contigs are built from scaffolds. | ||
d. Chromosomes are sequenced between FISH-stained locations and assembled according to these known cytological markers. |
a. Divergence, common ancestor | ||
b. Distance, common ancestor | ||
c. Divergence, distance | ||
d. Distance, adaptation |
a. Higher | ||
b. Lower | ||
c. Unchanged | ||
d. Negligible |
a. Genes which are not expressed differentially in tumor and normal cells. | ||
b. Genes which are overexpressed in normal cells. | ||
c. Genes which are overexpressed in tumor cells. | ||
d. Promoter sequences which are particularly active in tumor cells. |
a. RNA—protein interaction prediction. | ||
b. Gene prediction. | ||
c. Open reading frame prediction. | ||
d. Nucleic acid sequence translation to protein sequence. |
a. Euchromatin | ||
b. Heterochromatin | ||
c. Telomere | ||
d. Centromere |
a. Short known DNA sequences can be synthesized chemically directly on chip. | ||
b. All genes of an organism can be bound in microarrays, and these arrays can be used in differential gene expression studies. | ||
c. Microarrays made from the genome of an organism are typically probed with a whole genomic DNA probe made from the same organism. | ||
d. Fluorescent probes can be used to identify genes on microarrays. |
a. 10 and 6 | ||
b. 11 and 6 | ||
c. 14 and 6 | ||
d. 11 and 10 |
a. DNA extraction, restriction enzymes, and Southern blot | ||
b. DNA extraction, PCR, and Southern blot | ||
c. DNA extraction, restriction enzymes, and Western blot | ||
d. DNA extraction, PCR, and Western blot |
a. Overlapping chromosome fragments are sequenced continuously without leaving any gap behind. | ||
b. Both ends of random chromosome fragments are sequenced and then the fragments are assembled using computer programs. | ||
c. Scaffolds are sequenced and contigs are built from scaffolds. | ||
d. Chromosomes are sequenced between FISH-stained locations and assembled according to these known cytological markers. |
a. A single nucleotide change. | ||
b. A single codon change. | ||
c. A single amino acid change. | ||
d. A small genetic change. |
a. The ratio of poly-Q and poly-A | ||
b. The total length of poly-Q and poly-A | ||
c. Only the length of poly-Q | ||
d. Only the length of poly-A |
a. Proteomics | ||
b. Metagenomics | ||
c. Metabolomics | ||
d. Proteomics |
a. ABC | ||
b. ACB | ||
c. CAB | ||
d. CBA |
a. Metagenomics | ||
b. Envirogenomics | ||
c. Nature genomics | ||
d. Microbiomics |
a. Genetic map. | ||
b. Physical map | ||
c. Open reading frame | ||
d. Gene sequence |
a. Model organisms have genes similar to human genes. | ||
b. Model organisms are mainly used to highlight the differences between animals and humans. | ||
c. Model organisms can attract animal-loving students to genomics. | ||
d. A focus on the differences contributes to our understanding of genetic inheritance. |
a. Proteomics | ||
b. Metagenomics | ||
c. Metabolomics | ||
d. Proteomics |
a. Crossing over of the sister chromatids during meiosis I. | ||
b. Crossing over of the non-sister chromatids during meiosis I. | ||
c. Crossing over of the sister chromatids during meiosis II. | ||
d. Crossing over of the non-sister chromatids during meiosis II. |
a. Design gene therapy | ||
b. Clone animals | ||
c. Combine functional units of different proteins | ||
d. Generate novel cell types |
a. Cell differentiation | ||
b. Meiosis | ||
c. The locus of gene insertion | ||
d. Codon preference |
a. Transposable elements | ||
b. Proteases | ||
c. Epigenetic changes | ||
d. DNA methylation |
a. Lysosomes | ||
b. Extracellular space | ||
c. Nucleus | ||
d. Golgi |
a. Affinity chromatography and immunoprecipitation | ||
b. Exclusion chromatography and immunoprecipitation | ||
c. Western blot and exclusion chromatography | ||
d. Western blot and Northern blot |
a. Higher temperatures utilizing the increased Brownian motion | ||
b. The presence of complementing surfaces | ||
c. Processing enzymes which seal the protein in the right conformation with chemical bonds | ||
d. Chaperones that prevent premature aggregation of hydrophobic regions |
a. Dideoxy sequencing | ||
b. Edman degradation | ||
c. MALDI | ||
d. MS-MS |
a. Dideoxy sequencing | ||
b. Edman degradation | ||
c. MALDI | ||
d. MS-MS |
a. Can be modified posttranslationally | ||
b. Cannot be modified posttranslationally | ||
c. Are spontaneously secreted | ||
d. Are synthesized on ribosomes |
a. A separate surface from the DNA | ||
b. The surface as the DNA | ||
c. An antibody capture array | ||
d. A functional array |
a. Greatly | ||
b. Hardly | ||
c. Never | ||
d. Temporarily |
a. Simultaneously, enhancers | ||
b. Simultaneously, operons | ||
c. Consecutively, enhancers | ||
d. Consecutively, operons |
a. Eastern blot | ||
b. Northern blot | ||
c. Southern blot | ||
d. Western blot |
a. Size | ||
b. Shape | ||
c. Electric charge | ||
d. Polarity |
a. Burst | ||
b. Stay intact | ||
c. Shrink | ||
d. Divide |
a. Genomes | ||
b. Viruses | ||
c. Plasmids | ||
d. Vectors |
a. Reporter genes | ||
b. Selection genes | ||
c. Detection genes | ||
d. Promoters |
a. Knock-out | ||
b. Random insertion | ||
c. Mutated | ||
d. Inverted |
a. Providing extracellular matrix for | ||
b. Adding Ti plasmid to the growth medium of | ||
c. Inducing de-differentiation of | ||
d. Inducing viral gene transfer of |
a. Zinc | ||
b. Iron | ||
c. Selenium | ||
d. flavin |
a. Somatic | ||
b. Multipotent stem | ||
c. Totipotent stem | ||
d. Germ |
a. Only recessive homozygous | ||
b. Only homozygous traits | ||
c. Only dominant genes | ||
d. A desired combination of recessive and dominant genes |
a. Hair shaft | ||
b. Saliva | ||
c. Blood | ||
d. Milk |
a. Genetic mosaics | ||
b. Hybridomas | ||
c. Genetic mixtures | ||
d. Hybrids |
a. Somatic cell nuclear transfer | ||
b. Germ line nuclear transfer | ||
c. In vitro fertilization | ||
d. Recombineering |
a. Her shorter than average | ||
b. Her longer than average | ||
c. The absence of the | ||
d. The branching |
a. Forward genetic | ||
b. Reverse genetic | ||
c. Transgenic | ||
d. Mutagenic |
a. Substantial homologous | ||
b. Minimal homologous | ||
c. Substantial heterologous | ||
d. Minimal heterologous |
a. Site specific insertion; neutralization of position effects | ||
b. Neutralization of position effects; site specific insertion | ||
c. P element insertion; recombinases and integrases | ||
d. Recombinases and integrases; P element insertion. |
a. offer protection against | ||
b. enhance | ||
c. attenuate insect bites delivering | ||
d. intensify |
a. Preimplantation genetic diagnosis | ||
b. Postimplantation genetic diagnosis | ||
c. Prefertilization genetic diagnosis | ||
d. Genetic counseling |
a. Blue fluorescent protein | ||
b. Green fluorescent protein | ||
c. Red fluorescent protein | ||
d. Yellow fluorescent protein |
a. Insertion position | ||
b. Activity | ||
c. High copy number | ||
d. Inactivity |
a. DNA methylation | ||
b. Chromosomal rearrangement | ||
c. Missense mutation | ||
d. Chromosomal inversion |
a. 16 % | ||
b. 30% | ||
c. 40% | ||
d. 90% |
a. Stem cells; virus transformed cells | ||
b. Blood cells; virus transformed cells | ||
c. Stem cells; mutated cells | ||
d. Blood cells; mutated cells |
a. Zinc-finger nuclease | ||
b. Protease | ||
c. Antibody | ||
d. Lipase |
a. Every; every | ||
b. Every; a tumor | ||
c. A tumor, a tumor | ||
d. A tumor, every |
a. 0% | ||
b. 25% | ||
c. 50% | ||
d. 75% |
a. Point; malaria parasite | ||
b. Nonsense; malaria parasite | ||
c. Point; papillomavirus | ||
d. Nonsense; papillomavirus |
a. Gene gun, gold | ||
b. Gene gun, iron | ||
c. Particle gun, gold | ||
d. Particle gun, iron |
a. Turner | ||
b. Klinefelter | ||
c. Down | ||
d. Edwards |
a. Not wear off as we age; can | ||
b. Wear off as we age; can | ||
c. Not wear off as we age; cannot | ||
d. Wear off as we age; cannot |
a. Noncoding chromosomal regions | ||
b. Coding chromosomal regions | ||
c. One chromosome | ||
d. Sex chromosomes |
a. Simplicity of | ||
b. Instantaneous result of | ||
c. Statistical strength linked to | ||
d. Variety of available protocols for |
a. If a Y-typing is performed and shows that Mr. X’s Y chromosome is identical to the Y chromosome of Ms. Y’s son, then Mr. X must be the father. | ||
b. If a Y-typing is performed and shows that Mr. X’s Y chromosome is identical to the Y chromosome of Ms. Y’s son, then Mr. X or another man of his paternal line must be the father. | ||
c. If forensic DNA-typing is performed utilizing the standard 13 STR regions and shows that Mr. Y’s son has one-one allele of Mr. X’s each analyzed STR allele pair, then Mr. X must be the father. | ||
d. DNA fingerprinting cannot prove that Mr. X is the father of Ms. Y’s son. But if they are father and son, their friction ridge patterns will be identical on all of their fingers. |
a. Fermentation | ||
b. Extraction | ||
c. Bioaccumulation | ||
d. Bioamplification |
a. Single-species; multi-species | ||
b. Multi-species; single-species | ||
c. Single-layer; multi-layer | ||
d. Multi-layer; single-layer |
a. Biochemical reactions | ||
b. Microbes | ||
c. Plants | ||
d. Animals |
a. As carbonate-based concrete | ||
b. As Roman-style | ||
c. As concrete | ||
d. Underground |
a. Fermentation | ||
b. Extraction | ||
c. Bioaccumulation | ||
d. Bioamplification |
a. Simple; longer | ||
b. Technologically challenging; shorter | ||
c. Simple; shorter | ||
d. Technologically challenging; longer |
a. Bacteria | ||
b. Plants | ||
c. Birds | ||
d. Fishes |
a. Simple; longer | ||
b. Technologically challenging; shorter | ||
c. Simple; shorter | ||
d. Technologically challenging; longer |
a. Soluble in fat. | ||
b. Hydrophilic. | ||
c. Stable. | ||
d. Biologically active. |
a. Bacteria | ||
b. Plant | ||
c. Bird | ||
d. Fish |
a. Four | ||
b. Five | ||
c. Six | ||
d. Seven |
a. Chemostat | ||
b. Traditional liquid culture | ||
c. Semisolid culture | ||
d. Subculture |
a. Bioleaching | ||
b. Bioremediation | ||
c. In situ | ||
d. Biofilm |
a. Hydrogenases | ||
b. Hydrogen ion pumps | ||
c. Electron transport chain | ||
d. ATP |
a. isobutanol | ||
b. glucose | ||
c. penicillin | ||
d. hydrogen |
a. Just a fancy name for a multivitamin complex | ||
b. An antigen engineered into a plant we eat | ||
c. An attenuated oral vaccine, like the Sabin drops | ||
d. An antibody engineered into the plant we eat |
a. Saccharopolyspora erythraea | ||
b. Saccharomyces cerevisiae | ||
c. Streptomyces parvullus | ||
d. Clostridium cellulolyticum |
a. Lead to gene doping | ||
b. Initiate intensive wellness activities | ||
c. Can be easily accepted in sports | ||
d. Might to be legalized soon |
a. Genetic counseling | ||
b. Pharmacogenomics | ||
c. Pharmacokinetics | ||
d. Pharmacology |
a. Protect against the body’s immune response | ||
b. Bring another alternative to the market | ||
c. Follow these particles with body scanning | ||
d. Determine how fat particles leaves the body |
a. to build organs that are not rejected | ||
b. for future applications | ||
c. for donation | ||
d. in cloning |
a. Embryonic stem cells | ||
b. Somatic stem cells | ||
c. Adult stem cells | ||
d. Multipotent stem cells |
a. Mycoplasma Laboratorium | ||
b. Agrobacterium tumefaciens | ||
c. Escherichia coli | ||
d. Saccharomyces cerevisiae |
a. Radioimmunotherapy | ||
b. Radiotoxins | ||
c. Radiation therapy | ||
d. Chemotherapy |